My Companies
Notification
Account
Log Out
Login
USFDA classified InvaGen’s July inspection as VAI, a positive regulatory outcome that reduces uncertainty around Cipla’s New York facility.
Cipla Partners With Qilu To License Keytruda Biosimilar In US
Cipla Signs Exclusive License With SBP For TQB2102 HER2 ADC
Cipla Receives Seven Form 483 Observations At Pithampur Facility
Cipla Receives US FDA Approval For Generic Advair Diskus Inhaler
Cipla Appoints Dinesh Jain Global CFO As Ashish Adukia Moves To Internal Role